Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), today announced that the U.S. Food and Drug Administration (FDA) has granted...

Related Keywords

United States , Lise Kjems , Gastroenterol Hepatol , Product Service , Drug Administration , Ocelot Bio Inc , Drug Designation , Orphan Drug Designation , Ocelot Bio ,